Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free HLS Stock Alerts

HLS Therapeutics (HLS) Competitors

HLS Therapeutics logo
C$4.11 0.00 (0.00%)
As of 07/24/2026 04:00 PM Eastern
Compare

HLS vs. CPH, SUGR, FIRE, EPI, and ACB

Should you buy HLS Therapeutics stock or one of its competitors? MarketBeat compares HLS Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HLS Therapeutics include Cipher Pharmaceuticals (CPH), SugarBud Craft Growers (SUGR), Supreme Cannabis (FIRE), ESSA Pharma (EPI), and Aurora Cannabis (ACB). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Cipher Pharmaceuticals Neutral

5.0% of HLS Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

HLS Therapeutics currently has a consensus target price of C$6.00, indicating a potential upside of 45.99%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential upside of 4.62%. Given HLS Therapeutics' higher probable upside, equities research analysts clearly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to HLS Therapeutics' net margin of -18.42%. Cipher Pharmaceuticals' return on equity of 25.69% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Cipher Pharmaceuticals 60.82%25.69%7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.31-C$15.53M-C$0.32N/A
Cipher PharmaceuticalsC$50.94M8.10C$11.41MC$1.1913.66

HLS Therapeutics has a beta of -0.152102, suggesting that its share price is 115% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153706, suggesting that its share price is 15% more volatile than the broader market.

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 11 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to SugarBud Craft Growers?

HLS Therapeutics (TSE:HLS) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

SugarBud Craft Growers has a net margin of 2.11% compared to HLS Therapeutics' net margin of -18.42%. SugarBud Craft Growers' return on equity of 10.07% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
SugarBud Craft Growers 2.11%10.07%5.13%

5.0% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of SugarBud Craft Growers shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Comparatively, 30.2% of SugarBud Craft Growers shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HLS Therapeutics has a beta of -0.152102, indicating that its share price is 115% less volatile than the broader market. Comparatively, SugarBud Craft Growers has a beta of 2.768948, indicating that its share price is 177% more volatile than the broader market.

SugarBud Craft Growers has higher revenue and earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.31-C$15.53M-C$0.32N/A
SugarBud Craft GrowersC$662.89M0.42C$12.12MC$1.408.21

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled SugarBud Craft Growers'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
SugarBud Craft Growers Neutral

Summary

SugarBud Craft Growers beats HLS Therapeutics on 9 of the 11 factors compared between the two stocks.

How does HLS Therapeutics compare to Supreme Cannabis?

HLS Therapeutics (TSE:HLS) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Supreme Cannabis Neutral

5.0% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Supreme Cannabis has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. Supreme Cannabis' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Supreme Cannabis N/A N/A N/A

HLS Therapeutics has higher revenue and earnings than Supreme Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.31-C$15.53M-C$0.32N/A
Supreme CannabisC$53.29M0.00-C$23.65M-C$0.03N/A

Summary

Supreme Cannabis beats HLS Therapeutics on 5 of the 9 factors compared between the two stocks.

How does HLS Therapeutics compare to ESSA Pharma?

HLS Therapeutics (TSE:HLS) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

ESSA Pharma has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. ESSA Pharma's return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
ESSA Pharma N/A N/A N/A

ESSA Pharma has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.31-C$15.53M-C$0.32N/A
ESSA PharmaN/AN/AN/A-C$0.99N/A

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
ESSA Pharma Neutral

5.0% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

HLS Therapeutics and ESSA Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

HLS Therapeutics (TSE:HLS) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

HLS Therapeutics currently has a consensus target price of C$6.00, suggesting a potential upside of 45.99%. Aurora Cannabis has a consensus target price of C$7.17, suggesting a potential upside of 90.10%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

HLS Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.31-C$15.53M-C$0.32N/A
Aurora CannabisC$320.59M0.73-C$44.16M-C$2.14N/A

Aurora Cannabis has a net margin of -12.13% compared to HLS Therapeutics' net margin of -18.42%. Aurora Cannabis' return on equity of -7.25% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Aurora Cannabis -12.13%-7.25%-1.87%

5.0% of HLS Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Aurora Cannabis shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aurora Cannabis had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. Aurora Cannabis' average media sentiment score of 1.85 beat HLS Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Overall Sentiment
HLS Therapeutics Neutral
Aurora Cannabis Very Positive

HLS Therapeutics has a beta of -0.152102, meaning that its stock price is 115% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.268291, meaning that its stock price is 73% less volatile than the broader market.

Summary

Aurora Cannabis beats HLS Therapeutics on 11 of the 16 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HLS vs. The Competition

Export
MetricHLS TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$128.54MC$2.25BC$6.88BC$12.48B
Dividend Yield4.30%2.81%2.67%6.19%
P/E Ratio-12.845.0027.0036.95
Price / Sales2.311,642.24492.309.44
Price / Cash15.2210.1850.5482.29
Price / Book2.199.9110.284.39
Net Income-C$15.53MC$20.27BC$3.60BC$299.09M
7 Day PerformanceN/A-0.87%-1.29%0.61%
1 Month Performance-3.52%0.08%-0.38%1.06%
1 Year Performance-15.78%7.16%18.32%30.89%

HLS Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HLS
HLS Therapeutics
N/AC$4.11
flat		C$6.00
+46.0%		-16.8%C$128.54MC$55.74MN/A91
CPH
Cipher Pharmaceuticals
0.4834 of 5 stars		C$16.45
+0.4%		C$17.00
+3.3%		+29.6%C$417.68MC$50.94M13.825
SUGR
SugarBud Craft Growers
N/AC$11.27
+0.9%		N/A-14.3%C$271.26MC$662.89M8.0544
FIRE
Supreme Cannabis
N/AN/AN/AN/AC$259.40MC$53.29MN/A400
EPI
ESSA Pharma
N/AC$8.20
+7.2%		N/A+0.0%C$237.87MN/AN/A25

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel